Eric C. McGary - Publications, H-index & Citations

Eric C. McGary

kaiser permanente

16H指数

37论文数

1.4K被引数

收录论文 6

发表时间

Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in US patients with unresectable stage III NSCLC following concurrent chemoradiation

FUTURE ONCOLOGY

IF2.6

2025-12-01

PREAI

Haque, Reina; Mcgary, Eric; Yang, Mike Z.; Liu, Raymond; Suga, J. Marie; Chen, Liehong; Zhu, Zheng; Simmons, Daniel J.; Hsieh, Kristin; Cotarla, Ion; Sakoda, Lori C.

Half of oncologists fail to use ordered NGS results to guide their first-line treatment decision in advanced NSCLC: A retrospective study in a community-based integrated healthcare system

HELIYON

IF3.6

2024-08-01

OAAI

Megahed, Ahmed I.; Zheng, Dominick; Chen, Lie Hong; Haque, Reina; McGary, Eric C.

Inhibition of Platelet-derived Growth Factor-mediated Proliferation of Osteosarcoma Cells by the Novel Tyrosine Kinase Inhibitor STI571 (Expression of Concern of Vol 8, Pg 3584, 2002)

CLINICAL CANCER RESEARCH

IF10.2

2019-05-15

OAAI

McGary, Eric C.; Weber, Kristy; Mills, Lisa; Doucet, Michelle; Lewis, Valerie; Lev, Dina Chelouche; Fidler, Isaiah J.; Bar-Eli, Menashe

Mechanisms of action of rapamycin in gliomas

NEURO-ONCOLOGY

IF13.4

2005-01-01

OAAI

Heimberger, AB; Wang, E; McGary, EC; Hess, KR; Henry, VK; Shono, T; Cohen, Z; Gumin, J; Sawaya, R; Conrad, CA; Lang, FF

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo

JOURNAL OF INVESTIGATIVE DERMATOLOGY

IF5.7

2004-02-01

OAAI

McGary, EC; Onn, A; Mills, L; Heimberger, A; Eton, O; Thomas, GW; Shtivelband, M; Bar-Eli, M

Protein kinase Cα is an effector of hexamethylene bisacetamide-induced differentiation of friend erythroleukemia cells

EXPERIMENTAL CELL RESEARCH

IF3.5

1999-02-01

PREAI

Mallia, CM; Aguirre, V; McGary, E; Tang, Y; Scandurro, AB; Liu, C; Noguchi, CT; Beckman, BS

研究方向